Advicenne specializes in the research and development of drugs for the treatment of neglected neurological and nephrological diseases, mostly among children. At the end of 2025, the group had one product in clinical development phase: ADV7103 for the treatment of distal renal tubular acidosis and for the treatment of cystinuria.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
09/26/09	€0.6400	+1.59%	22,748
06/26/06	€0.6300	-0.32%	8,745
05/26/05	€0.6320	+0.32%	9,356
04/26/04	€0.6300	-4.26%	23,657
03/26/03	€0.6580	+1.86%	3,276

Real-time Euronext Paris

More quotes

Analysis / Opinion

OHB and Soitec ride supportive news flow, Advicenne tumbles

August 31, 2026 at 03:24 pm IST

More analyses

EPS Estimates

Evolution of Analysts' Estimates - EPS - Advicenne

Revisions to estimates

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Advicenne

Company calendar

Market Closed - Euronext Paris 10:25:00 09/11/2026 pm IST			5-day change	1st Jan Change
0.6400 ^EUR	+1.59%		-1.08%	-63.01%

12/10	Advicenne Secures EUR1 Million from Existing Bond Financing Contract	MT
12/10	Advicenne Extends Its Cash Runway to 2028 Through Bond Financing and Strong Operational Performance	CI

Market Cap	93.11L 1.04Cr 85.68L 77.76L 1.47Cr 98Cr 1.51Cr 10Cr 4.09Cr 52Cr 3.92Cr 3.83Cr 164.86Cr	P/E 2026 *	-1.36x	P/E 2027 *	-1.45x
Enterprise Value	3.24Cr 3.63Cr 2.98Cr 2.71Cr 5.13Cr 340.35Cr 5.26Cr 36Cr 14Cr 182.21Cr 14Cr 13Cr 573.89Cr	EV / Sales 2026 *	4.91x	EV / Sales 2027 *	4.81x
Free-Float	94.2%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Euronext Paris	ALDVI	Real-time
Börse Stuttgart	3MM	Delayed
CBOE		Real-time
Deutsche Boerse AG	3MM	Delayed
Boerse Muenchen	3MM	Real-time
CBOE		Real-time

12/10	Advicenne Secures EUR1 Million from Existing Bond Financing Contract	MT
12/10	Advicenne Extends Its Cash Runway to 2028 Through Bond Financing and Strong Operational Performance	CI
18/09	Advicenne returns to profit in the first half of 2026
17/09	Advicenne S.A. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
31/08	Advicenne Decides To Withdraw Its ADV7103 New Drug Application In The USA	CI
31/08	OHB and Soitec ride supportive news flow, Advicenne tumbles
31/08	Advicenne Withdraws US Application for Distal Renal Tubular Acidosis Drug	MT
21/07	Advicenne's Distal Renal Tubular Acidosis Medicine Secures Reimbursement in Spain	MT
16/07	Advicenne S.A. Reports Sales Results for the First Half of 2026	CI
02/07	UK Regulator Grants 'Unlimited Renewal' of Advicenne's Distal Renal Tubular Acidosis Drug	MT
01/07	Advicenne Announces Unlimited Renewal of Marketing Authorization for Sibnayal in United Kingdom	CI
23/06	Advicenne secures its cash runway through the second quarter of 2027
23/06	Advicenne secures its cash runway through the second quarter of 2027

Advicenne Share Price

Stocks

ALDVI

FR0013296746

Pharmaceuticals

Valuation: Advicenne

Chart: Advicenne

Latest news: Advicenne

Analysts' recommendations: Advicenne

Press Releases: Advicenne

News in other languages: Advicenne

Quotes and Performance

Price Extremes

Managers and Directors: Advicenne

Latest insider transactions

Biopharmaceuticals

Financials

Company Profile

Quotes

Analysis / Opinion

Annual profits - Rate of surprise

03/11	Advicenne Informs About the Ongoing Safeguard Procedure	BU
21/10	Advicenne : reports First Half financial results as of June 30, 2026, and updates on its activities	PU
12/10	Advicenne Extends Its Cash Runway to 2028 Through Bond Financing and Strong Operational Performance	BU
17/09	Advicenne Reports First Half Financial Results as of June 30, 2026, and Updates on Its Activities	BU
31/08	Advicenne decides to withdraw its ADV7103 New Drug Application in the USA	BU

03/11	Advicenne : information relative à la procédure de sauvegarde
21/10	Advicenne : présente ses résultats financiers semestriels au 30 juin 2026 et fait le point sur ses activités
12/10	Bourse : LVMH en piste ce soir, Stellantis sort une 2CV, NVidia et Amazon s'offrent des garanties
12/10	Advicenne prolonge sa visibilité financière jusqu'en 2028
12/10	La Bourse se découvre une passion pour le cocktail taux-croissance

1 day	+1.59%
1 week	-1.08%
Current month	-1.08%
1 month	+3.23%
3 months	-61.45%
6 months	-26.44%
Current year	-63.01%

1 week	0.63	0.67
1 month	0.63	0.77
Current year	0.61	2.35
1 year	0.61	2.35
3 years	0.61	3.08
5 years	0.61	10.5
10 years	0.61	16.25

Manager	Title	Age	Since
Didier Laurens CEO	Chief Executive Officer	59	03/05/2021
Delphine Dumas CTO	Chief Tech/Sci/R&D Officer	-	01/09/2025
Véronique Leblanc CTO	Chief Tech/Sci/R&D Officer	-	01/04/2023

Director	Title	Age	Since
André Ulmann BRD	Director/Board Member	-	23/06/2017
Catherine Dunand BRD	Director/Board Member	65	09/03/2017
Charlotte Sibley BRD	Director/Board Member	78	20/09/2018

Date	Insider	Type	Main position	Quantity	% Market Cap.
30/12/20	Nathalie Lemarié	Sell	General Counsel	998	0.0123%
29/12/20	Nathalie Lemarié	Sell	General Counsel	1,000	0.0124%
25/12/20	Nathalie Lemarié	Sell	General Counsel	1,000	0.0124%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ADVICENNE	+1.59%	-1.08%	-60.83%	-68.55%	1.02Cr
ELI LILLY AND COMPANY	+4.43%	+0.20%	+46.26%	+139.10%	1,20600Cr
JOHNSON & JOHNSON	+1.17%	+4.23%	+49.68%	+91.30%	66TCr
ABBVIE INC.	+0.70%	+1.43%	+33.95%	+112.23%	51TCr
ROCHE HOLDING AG	+2.77%	-0.57%	+49.44%	+68.42%	38TCr
MERCK & CO., INC.	+0.30%	+0.06%	+71.12%	+45.00%	36TCr
NOVARTIS AG	+0.29%	-0.24%	+30.84%	+57.23%	31TCr
ASTRAZENECA PLC	+0.98%	+0.76%	+9.04%	+38.31%	29TCr
AMGEN INC.	+1.01%	+0.01%	+43.82%	+76.28%	25TCr
GILEAD SCIENCES, INC.	+1.47%	-0.13%	+43.98%	+126.87%	21TCr
Average	+1.53%	-1.65%	+31.73%	+68.62%	41.8TCr
Weighted average by Cap.	+2.18%	-1.96%	+43.77%	+96.29%

	2026 *	2027 *
Net sales	66L 73.94L 60.73L 55.12L 1.04Cr 69Cr 1.07Cr 7.27Cr 2.9Cr 37Cr 2.78Cr 2.72Cr 116.86Cr	80L 89.63L 73.61L 66.81L 1.27Cr 84Cr 1.3Cr 8.81Cr 3.51Cr 45Cr 3.36Cr 3.29Cr 141.65Cr
Net income	-67L -75.06L -61.65L -55.95L -1.06Cr -70Cr -1.09Cr -7.38Cr -2.94Cr -38Cr -2.82Cr -2.76Cr -118.64Cr	-62L -69.46L -57.05L -51.78L -98.13L -65Cr -1.01Cr -6.82Cr -2.72Cr -35Cr -2.61Cr -2.55Cr -109.78Cr
Net Debt	2.31Cr 2.59Cr 2.13Cr 1.93Cr 3.66Cr 242.58Cr 3.75Cr 25Cr 10Cr 129.87Cr 9.71Cr 9.51Cr 409.03Cr	2.92Cr 3.27Cr 2.69Cr 2.44Cr 4.62Cr 306.63Cr 4.74Cr 32Cr 13Cr 164.16Cr 12Cr 12Cr 517.04Cr